Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients

Internal Medicine

Volumn 44, Issue 5, 2005, Pages 417-421

  Yoshioka, Keiji ^a   Yoshida, Toshihide ^b,c   Takakura, Yasuto ^b   Umekawa, Tsunekazu ^b   Kogure, Akinori ^b   Toda, Hitoshi ^d   Yoshikawa, Toshikazu ^b  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

^d Sakazaki Clinic   (Japan)

Author keywords

Diabetic retinopathy; RAGE gene; Single nucleotide polymorphism (SNP)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; LIPID; PRIMER DNA;

ADULT; AGE; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANALYSIS; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROLIFERATIVE RETINOPATHY; PROTEIN POLYMORPHISM;

AGE FACTORS; ALLELES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; LIPIDS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 21244439504     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.417     Document Type: Article

References (36)

1. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 58: S26-S30, 2000.
2. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation endproducts: a nephrologist's perspective. Am J Kidney Dis 35: 365-380, 2000.
3. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14: 1521-1528, 1994.
4. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24: 1342-1349, 2004.
5. Sakurai S, Yonekura H, Yamamoto Y, et al. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 14: S259-S263, 2003.
6. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497, 1999.
7. Kumaramanickavel G, Ramprasad VL, Spripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications 16: 391-394, 2002.
8. Kankova K, Vasku A, Hajek D, Zaheisky J, Vasku V. Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 22: 1745, 1999.
9. Liu L, Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy. Diabetes Care 22: 646, 1999.
10. Kankova K, Beranek M, Hajek D, Vlkova E. Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the RAGE gene are not associated with diabetic retinopathy in NIDDM: pilot study. Retina 22: 119-121, 2002.
11. JiXong X, BiLin X, MingGong Y, ShuQin L. -429T/C and -374T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetes Care 26: 2696-2697, 2003.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagosis and Classification of Diabetes Mellitus. Diabetes Care 26 (Suppl. 1): S5-S20, 2003.
13. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347: 1916-1923, 2002.
14. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945, 1996.
15. Nagi DK, Mansfield MW, Stickland MH, Grant PJ. Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Diabetic Med 12: 997-1001, 1995.
16. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41: 47-53, 1998.
17. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 71: 731-736, 1994.
18. Nagi DK , McCormack U, Mohamed-Avi V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promotor (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 20: 1304-1309, 1997.
19. Kankova K, Muzik J, Karaskova J, et al. Duration of non-insulin-dependent diabetes mellitus and the TNF-beta NcoI genotype as predictive factors in proliferative diabetic retinopathy. Opthalmologica 215: 294-298, 2001.
20. Kumaramanickavel G, Spripriya S, Vellanki RN, et al. Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India. Diabetes Res Clin Pract 54: 89-94, 2001.
21. Kao YL, Donaghue K, Chan A, Knight J, Silink M. An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Pract 46: 155-160, 1999.
22. Wang Y, Ng MC, Lee SC, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26: 2410-2415, 2003.
23. Taverna MJ, Sola A, Guyot-Argenton C, et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk of severe diabetic retinopathy. Diabetic Med 19: 240-245, 2002.
24. Warpeha KM, Xu W, Liu L, et al. Genotyping and functional analysis of a polymorphic (CCTTT) (n) repeat of NOS2A in diabetic retinopathy. FASEB J 13: 1825-1832, 1999.
25. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51: 1635-1639, 2002.
26. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VGEF gene with proliferative diabetic retinopathy but not proteinuria. Diabetes 53: 861-864, 2004.
27. Beranek M, Kankova K, Benes P, et al. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. Am J Med Genet 109: 278-283, 2002.
28. Maeda M, Yamamoto I, Fukuda M, et al. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care 26: 547-548, 2003.
29. Yoshioka K, Yoshida T, Takakura. Y, et al. No association between MTHFR gene polymorphism and diabetic retinopathy in type 2 diabetic patients without overt nephropathy. Diabetes Care 26: 1947-1948, 2003.
30. Yoshioka K, Yoshida T, Takakura Y, et al. Fatty acid binding protein gene 2 polymorphism is not associated with diabetic retinopathy in Japanese type 2 diabetic patients. Horm Metab Res 35: 625-627, 2003.
31. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97: 238-243, 1996.
32. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001.
33. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: Prevalence in type 2 diabetes and ethnic groups. Diabetes 47: 1155-1157, 1998.
34. Matsunaga-Irie S, Murayama T, Yamamoto Y, et al. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 27: 303-307, 2004.
35. Poirier O, Nicaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 50: 1214-1218, 2001.
36. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001.